Amgen’s Antitrust Concerns Ignite Broader Apprehensions About Pharmaceutical Mergers
In a significant development, Amgen, the multinational biopharmaceutical company, has found itself in the crosshairs of an antitrust lawsuit. The unexpected action has sent ripples through the pharmaceutical industry, leading to wider apprehensions about potential deals and mergers. The FTC’s Unexpected Move The U.S. Federal Trade Commission (FTC), in an unexpected turn of events, filed…